How a radiopharma up-and-comer builds momentum in a surging space

As far as cancer treatments go, radiopharmaceuticals are conceptually one of the simplest — radioactive substances are very good at killing cancer cells, after all. And as targeting mechanisms improve, Big Pharma has taken a renewed interest in the area’s potential, driving more innovation at smaller companies developing radiopharmaceuticals of their own.

While the pharma industry may be seeing a radio-renaissance, the idea has been around since the years following World War II, said Jack Hoppin, CEO of the radiopharmaceutical company Ratio Therapeutics.